BullFrog AI Holdings, Inc.

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company in the United States, focusing on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare. The company provides bfLEAP, an analytical AI/ML platform designed to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, as well as other organizations. Bullfrog AI is also engaged in the development of several therapeutic candidates. These include BF-222, a novel formulation of mebendazole, which is currently in the first phase for the treatment of Glioblastoma. Additionally, BF-223, a novel prodrug of mebendazole, is in the preclinical stage for the treatment of Glioblastoma. The company is also developing BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. Bullfrog AI holds licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. It also has an agreement with Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company has a partnership with the Lieber Institute for Brain Development (LIBD) to facilitate the discovery and development of precision treatments for CNS disorders. Bullfrog AI Holdings, Inc. was founded in 2017 and is headquartered in Gaithersburg, Maryland.